Valuation: Nektar Therapeutics

Market Cap 1.49B 1.32B 1.23B 1.12B 2.12B 143B 2.14B 14.93B 5.79B 73.12B 5.59B 5.47B 235B P/E 2026 *
-5.39x
P/E 2027 * -4.25x
Enterprise Value 1.4B 1.24B 1.16B 1.06B 2B 135B 2.01B 14.05B 5.44B 68.8B 5.26B 5.14B 221B EV / Sales 2026 *
33.4x
EV / Sales 2027 * 22.4x
Free-Float
99.62%
Yield 2026 *
-
Yield 2027 * -
1 day-7.26%
1 week-23.62%
Current month-28.02%
1 month-40.09%
3 months-38.65%
6 months-43.40%
Current year+3.07%
1 week 43.51
Extreme 43.51
62.4
1 month 43.51
Extreme 43.51
77.76
Current year 33.4
Extreme 33.4
109
1 year 33.4
Extreme 33.4
109
3 years 6.19
Extreme 6.188996
109
5 years 6.19
Extreme 6.188996
280.35
10 years 6.19
Extreme 6.188996
1,670.4
Manager TitleAgeSince
Chief Executive Officer 73 01/01/2007
Director of Finance/CFO 60 15/05/2026
Chief Tech/Sci/R&D Officer 52 01/07/2015
Director TitleAgeSince
Director/Board Member 72 01/08/2000
Chairman 69 01/05/1992
Director/Board Member 73 01/02/2007
Date Insider Type Main position Quantity % Market Cap. Importance
23/9/26 Free

Director

6,000 0.0176%
23/9/26 Free

Director

6,000 0.0176%
23/9/26 Free

Director

6,000 0.0176%
Change 5-day change 1-year change 3-year change Capi.($)
-7.26%-23.62%-27.97%+409.80% 1.49B
+4.16%+3.04%+49.37%+94.17% 74.16B
-3.11%-3.53%+21.92%+74.60% 57.39B
+0.89%-0.63%+4.28%+34.51% 47.64B
+0.36%+0.81%+352.17%+689.61% 44.29B
-0.96%-4.50%+26.36%+33.18% 42.5B
-0.20%-0.77%+3.74%+100.60% 40.71B
-0.54%+2.93%+9.31%+50.41% 30.97B
-2.68%+2.92%+29.63%+19.50% 28.53B
+0.05%-1.64%-7.28%-14.06% 24.34B
Average -0.93%-2.89%+46.15%+149.23% 39.2B
Weighted average by Cap. +0.09%-0.93%+58.44%+130.97%

Financials

2026 *2027 *
Net sales 41.88M 37.21M 34.73M 31.65M 59.7M 4.03B 60.25M 420M 163M 2.06B 157M 154M 6.61B 57M 50.64M 47.27M 43.08M 81.25M 5.48B 82.01M 572M 222M 2.8B 214M 209M 8.99B
Net income -245M -217M -203M -185M -349M -23.52B -352M -2.46B -951M -12.02B -919M -899M -38.59B -354M -314M -293M -267M -504M -34.01B -509M -3.55B -1.38B -17.38B -1.33B -1.3B -55.79B
Net Debt -88.02M -78.2M -72.99M -66.53M -125M -8.46B -127M -883M -342M -4.33B -330M -323M -13.88B -210M -187M -174M -159M -300M -20.22B -303M -2.11B -818M -10.34B -790M -773M -33.18B
Logo Nektar Therapeutics
Nektar Therapeutics is a clinical-stage biotechnology company. It is focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body’s immune response to fight cancer. Its lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel regulatory T cell stimulator being evaluated in two Phase IIb clinical trials, one in atopic dermatitis and one in alopecia areata. Its pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. It is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials.
Employees
63
Date Price Change Volume
02/10/26 USD 43.58 -7.26% 2,923,413
01/10/26 USD 46.99 -22.39% 6,271,722
30/09/26 USD 60.55 +2.20% 1,210,000
29/09/26 USD 59.24 -1.92% 1,816,418
28/09/26 USD 60.40 +5.85% 1,376,161
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
43.58USD
Average target price
141.40USD
Spread / Average Target
+224.46%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. NKTR Stock